Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DENTSPLY SIRONA Inc. (Nasdaq: XRAY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, strategic reviews and key governance decisions.
In its Form 8-K filings, Dentsply Sirona reports results of operations and financial condition for recent quarters, including segment and geographic performance, non-GAAP metrics and information about goodwill and intangible asset impairments. The company also files 8-Ks to disclose changes in executive officers, retention equity incentive awards, formation of board-level committees and updates on matters such as the conclusion of an SEC Division of Enforcement investigation without enforcement action.
Other filings referenced by the company, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, contain detailed risk factors, financial statements and management discussion that are incorporated by reference in forward-looking statements. These documents provide context on how Dentsply Sirona views risks related to its dental products, technologies, segments and global operations.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the significance of each document in straightforward language. Real-time updates from EDGAR help users follow new 8-Ks reporting quarterly earnings, leadership transitions or strategic portfolio decisions, as well as periodic reports like 10-K and 10-Q when available. For those monitoring governance and incentives, filings also describe compensation arrangements, retention grants and board committee structures. This page is a focused resource for understanding how Dentsply Sirona communicates material information, manages regulatory obligations and frames risks and opportunities in its official SEC documents.
DENTSPLY SIRONA Inc ownership update: The Vanguard Group filed an Amendment No. 18 to a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the class. The filing explains an internal realignment at The Vanguard Group that disaggregated certain subsidiaries for separate reporting in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration, and lists Vanguard's registered address in Malvern, Pennsylvania.
Southpoint Master Fund, LP and affiliated filers reported beneficial ownership of 10,000,000 shares of Dentsply Sirona Inc. Common Stock (CUSIP 24906P109), representing 5.0% of the class. The shares are reported as held with shared voting and shared dispositive power of 10,000,000.
The filing is a joint Schedule 13G listing Southpoint Master Fund, LP; Southpoint Capital Advisors LP; Southpoint Capital Advisors LLC; Southpoint GP, LP; Southpoint GP, LLC; and John S. Clark II as reporting persons. The ownership percentages are calculated using 199,749,333 shares outstanding as of February 20, 2026.
Scavilla Daniel T reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. reported that President and CEO Daniel T. Scavilla received a grant of 3,554.869 shares of phantom stock under a Supplemental Executive Retirement Plan. The phantom stock has an economic value equivalent to common stock at a reference price of $11.43 per share.
The award represents a SERP contribution for the year 2025 based on the 12/31/25 closing price and is held as a derivative interest. These phantom shares will be settled in common stock upon the executive’s termination of employment, and there were 3,554.869 phantom stock units reported as held directly after this grant.
Denti Aldo Mariano Roberto reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. executive Aldo Mariano Roberto Denti, EVP and Chief Commercial Officer, received an award of 829.396 shares of phantom stock under the company’s Supplemental Executive Retirement Plan for 2025, based on the 12/31/25 closing price. Each phantom share is economically equivalent to one share of common stock and becomes payable in common stock when his employment terminates. After this grant, his reported phantom stock balance is 829.396 shares.
Czerney Kevin reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. reported that VP and Chief Accounting Officer Kevin Czerney received a grant of 2,853.551 shares of phantom stock under the company’s Supplemental Executive Retirement Plan. Each phantom share is economically equivalent to one common share and becomes payable in common stock when his employment ends.
Following this award, Czerney holds a total of 6,346.9846 phantom stock shares directly, all tied to the company’s common stock and described as a SERP contribution for 2025 based on the 12/31/25 closing price.
DENTSPLY SIRONA Inc. director-related entity buys shares. A trust associated with director Gregory T. Lucier purchased 15,000 shares of common stock in an open-market transaction at a weighted average price of $12.445 per share. Following this purchase, the trust held 65,000 shares indirectly for his benefit.
Separate indirect holdings reported, with no new transactions shown, include 24,901.284 shares held by a family partnership and 21,000 shares held by a Gregory Lucier IRA.
DENTSPLY SIRONA Inc. director James D. Forbes reported an open-market purchase of common stock. On March 9, 2026, he bought 5,000 shares at $12.48 per share. After this transaction, his directly owned position increased to 10,000 common shares of the company.
DENTSPLY SIRONA Inc. executive Kevin Czerney, VP and Chief Accounting Officer, reported equity awards granted on March 4, 2026. He received stock options for 10,400 shares and a grant of 13,690 shares of common stock.
The common stock award consists entirely of restricted stock units that vest in one-third installments over three years, ending March 4, 2029. The stock options also vest in one-third annual increments through March 4, 2029 and carry an exercise price equal to 110% of the closing share price on the grant date.
Frohning Andrea L. reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. reported that SVP and CHRO Andrea L. Frohning received equity awards on March 4, 2026. She was granted stock options for 121,600 shares and an award of 26,786 restricted stock units, both vesting in equal one-third installments annually through March 4, 2029.
DENTSPLY SIRONA Inc. executive Aldo Mariano Roberto Denti, EVP and Chief Commercial Officer, reported receiving new equity awards. On March 4, 2026, he was granted stock options for 270,200 shares and 59,524 shares of common stock through restricted stock units. Both the RSUs and options vest in one-third annual installments over three years, ending March 4, 2029. The options have an exercise price set at 110% of the company’s closing common stock price on the grant date, aligning the award’s value with future share performance.